Reported results
- Research and development expenses were $28.8 million for the three months ended September 30, 2026 (GAAP).
- General and administrative expenses were $13.1 million for the three months ended September 30, 2026 (GAAP).
- Net loss was $39.1 million, or $0.10 per share, for the three months ended September 30, 2026 (GAAP).
- Cash and cash equivalents were $422.8 million as of September 30, 2026 (GAAP).
Guidance
- Expect to report topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.
- Expect FDA feedback following CMC Type B meeting in the first quarter of 2027.
- Expect to nominate an additional gene therapy development candidate and commence preclinical development activities in the first half of 2027.
- Expect that current cash resources will support planned operating expenses and capital requirements into the second half of 2028.
Price and volatility reaction
The stock moved -1.6% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 4.28 | 2026-11-11 |
| Close after release | 4.21 | 2026-11-12 |
| Realised move | -1.6% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
